Growth factor activity of IL-6 in the synovial fluid of patients with rheumatoid arthritis.
OBJECTIVE
We set out to determine whether the ability of synovial fluids (SF) in patients with rheumatoid arthritis (RA) to facilitate the proliferation of synovial tissue-derived fibroblastic cell lines was related to the presence of growth factors and/or cytokines.


METHODS
The growth factor activity of 20 RA SF was measured by their ability to induce anchorage-independent growth of the rat NRK-49F (49F) fibroblastic strain. The presence of transforming growth factor-beta (TGF-beta) and platelet-derived growth factor (PDGF) was also assessed using neutralising anti-TGF-beta or anti-PDGF-AB mAbs. Cytokines were measured by functional assays or ELISA:


RESULTS
We observed a correlation between growth factor activity and the IL-6 levels in SF. Both were correlated to the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in SF and serum. IL-6 (at concentrations above 10(4) U/ml), synergized with growth factors in the induction of the anchorage independent (AI) growth of 49F cells. Pretreatment of SF with a neutralising anti-IL-6 mAb substantially reduced the capacity of these SF to induce AI growth of 49F cells, confirming the growth factor activity of IL-6 in this test. In contrast, IL-6 alone or in association with PDGF, epidermal growth factor (EGF) or TGF-beta had no effect on the anchored growth of synovial tissue-derived fibroblasts, and treatment of SF with a neutralising anti-IL-6 mAb did not affect their ability to increase the growth rate of synovial tissue-derived fibroblasts.


CONCLUSIONS
These results strongly suggest that IL-6 is responsible for the observed correlation between the growth factor activity of SF and inflammatory indexes such as ESR and CRP. However, neither IL-6 nor PDGF were responsible for the observed positive effect of SF on synovial fibroblastic cell lines.
Monier
S
S
INSERM U291, Montpellier, France.
Rème
T
T
Cognot
C
C
Gao
Q L
QL
Travaglio-Encinoza
A
A
Cuchacovich
M
M
Gaillard
J P
JP
Jorgensen
C
C
Sany
J
J
Dupuy d'Angeac
A
A
D000328:Adult; D000368:Aged; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000503:physiopathology*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D002455:Cell Division / Q000502:physiology; D002460:Cell Line; D004815:Epidermal Growth Factor / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D051379:Mice; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000502:physiology*; D051381:Rats; D013582:Synovial Fluid / Q000378:metabolism*; D016212:Transforming Growth Factor beta / Q000502:physiology*
D015850:Interleukin-6; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D004815:Epidermal Growth Factor; D002097:C-Reactive Protein